Pfizer is acquiring Metsera and its pipeline of obesity medications that could offer dosing and tolerability advantages for patients as well as a manufacturing edge for the pharma giant. Key data Phase 2 readouts for Metsera’s lead GLP-1 drug candidate are expected in 2026.
The post Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More appeared first on MedCity News.
